NCT00498992Unknown不适用
Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching
研究概览
简要总结
RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer.
PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor therapy for cancer.
详细描述
OBJECTIVES:
Primary
- Determine the efficacy of Regenecare® wound gel in alleviating pain and itching in patients who develop an acneiform rash while undergoing treatment with cetuximab or other EGFR inhibitor therapy for cancer.
Secondary
- Determine the efficacy of this drug in reducing the severity of rash in these patients.
- Determine the efficacy of this drug in reducing the redness and appearance of the rash in these patients.
- Determine the tolerability of this drug in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Supportive Care
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosis of cancer
- •Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial
- •PATIENT CHARACTERISTICS:
- •Not pregnant or nursing
- •No known history of hypersensitivity to amine-type local anesthetics or to other components of MPM Regenecare® wound gel
- •No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that would interfere with assessment of EGFR inhibitor-induced rash
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •No other concurrent topical facial creams or lotions
排除标准
- 未提供
结局指标
主要结局
Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching
次要结局
- Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of rash
- Tolerability of Regenecare® wound gel as assessed by NCI CTCAE v3.0
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With RadiotherapyHead and Neck CancerNCT01520701Centre Francois Baclesse130
已完成
2 期
Retinyl Palmitate-loaded Ethosomes in Acne VulgarisFacial Acne VulgarisNCT04080869Assiut University20
已完成
不适用
aser versus conventional treatment for active acne in primary careAcne vulgarisSkin and Connective Tissue DiseasesISRCTN78675673West London Research Network (WeLReN) (UK)40
撤回
不适用
A Novel Skin Barrier Protectant for Acute RadiodermatitisHead and Neck CancerSkin DiseasesRadiation ToxicityRadiodermatitisRadiation DermatitisNCT04593914Jessa Hospital
终止
2 期
Beta Blocker for Chronic Wound HealingBurnsUlcerNCT00368602University of California, Davis40